Testing the drug ERAS-801 in people with grade IV glioblastoma or gliosarcoma that has an EGFR change
Original title: ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing a drug called ERAS-801 in people whose grade IV brain tumor has a change in a protein called EGFR.
Who this trial is for. This trial is for people with grade IV glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary or gliosarcoma that can be removed by surgery, and whose tumor is IDH wildtype and has extra EGFR or a change in EGFR. It is testing a drug called ERAS-801 to see how safe it is and what side effects it causes.
Where it stands. This trial has not reported results. It is measuring how safe ERAS-801 is and what side effects people have. The answer is not in yet.
What this means, and what it doesn't
What it could mean: EGFR is a protein on the surface of some cells. It tells those cells to divide, and some tumor cells carry too much of it. ERAS-801 is made to block EGFR, and it can reach the brain and spinal cord. Researchers hope it may shrink tumor cells or slow their growth. If your tumor fits this picture, you could ask your care team whether this trial is worth looking into.
What it doesn't mean: This does not mean ERAS-801 works. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that you will be helped. This is not a promise of a cure.
Source: ClinicalTrials.gov, July 20, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.